KRAS and lung adenocarcinoma: To determine if the observed mitochondrial changes in SETD2-deficient tumors result in increased mitochondrial function and consequential ATP production, we generated cell lines expressing two distinct shRNAs targeting Setd2 in the H2009 human lung adenocarcinoma cell line that harbors oncogenic KRAS and p53 mutations22.